Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. - Wikidata - awgldk - TriplyDB

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

http://www.wikidata.org/entity/Q34239292

about

Discovery of new biomarkers for malignant mesothelioma Consensus report of the 2015 Weinman International Conference on Mesothelioma Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.Malignant pleural mesothelioma: an update on diagnosis and treatment options.The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.Year in review 2014. Paediatric and adult clinical studies.Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.The diagnosis of pleural effusions.Biomarkers and prognostic factors for malignant pleural mesothelioma.FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study.Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.Malignant Mesothelioma: Time to Translate?Diagnosis and prognosis-review of biomarkers for mesothelioma.Diagnostic approach to pleural diseases: new tricks for an old trade.Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment.Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies.Interpretation of pleural fluid biochemistry.Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies.New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.Serum mesothelin and other biomarkers: what have we learned in the last decade?Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer

P2860

Q26849620-F5C09E95-AF65-452F-88E9-AA1F759703BE Q27908468-B82CE587-1FBF-4D6C-81E2-8505396D435F Q28082088-BE49047E-AB0C-4A2B-A204-291E19042C66 Q28389185-E079C0CE-8013-4C49-B0D0-4867D03DE1D9 Q33556551-68EAEE8E-739A-4EA1-B453-2D8890C5B568 Q33890558-0F5132DD-3DDF-47AC-8DBD-36F153499BEB Q34513958-729B8A57-CA5D-4EFC-84F0-E863B5B9139F Q35274923-120C9124-464D-4F19-8B25-587AF5294091 Q36081391-6B5D0430-4048-4FD3-968A-D14A518FFEFB Q36320997-D1314D2C-8BFC-40C0-B2FF-3ED6D96B8262 Q36901529-A720AEFA-C76E-4E8A-8E1D-7A12473466EF Q37516709-9F3D136A-B7F4-4FAA-8A2C-8EBEE21CBA63 Q37687605-5103ADEB-CE5C-438D-A506-F8783F55CD22 Q38376166-400D7A70-B6F1-45BC-B43A-82694517FFCD Q38585167-2AFB428C-D6B5-4A8A-B7A3-A7847ECA0BEA Q38602583-AEA7C8B1-AE8E-43E3-80D0-66020B11A18F Q38660038-2FD5E0B8-E7E0-4D6A-8D4E-FF6B19471ED1 Q38935080-4BA8480D-E52C-4B96-9282-7F5E82E4C59C Q38987622-A54A5FC0-C0EC-4332-9BA4-16287F60C850 Q39012195-5627F7E8-31BE-43B2-BF17-521AB741A324 Q39124644-C4250703-5BAE-4B1C-9D08-F47E65E46B04 Q39366003-C88B0025-284C-4BA8-A26F-B330EBC840D4 Q39434249-9C311479-7520-401E-8735-2BD02E66B86D Q40104700-878CB7D6-B4A5-4536-B1A4-64C1CCA7A6FD Q40189722-3AAD49D9-AEF6-4B2C-9C7D-C94064153FB5 Q41234207-17D82B39-D9F7-462A-B7BF-0A3254D310F7 Q41593380-666C6A21-B992-42CC-842B-ED83AD82768D Q42349929-409D43C1-B33E-4E42-B01D-E0475C4D3BAE Q45824718-B577098C-A840-4399-932B-435F6967A295 Q48169833-9FDB1105-D14C-4D71-9665-89BAA2931063 Q50487668-6292E5D2-C736-4EA7-97D0-C412BA0361D4 Q51676810-627F6D93-4939-48A0-8A75-02964A4050C9 Q52581757-4144D8CD-D426-4F85-AA7A-8F39624EA8EA Q52672878-1220AF8F-8500-4D44-A484-C615B5C2B618 Q52672883-2D0F0F29-3E85-4C72-AE44-E1151608DCAF Q53248796-2BDCEB5B-E17A-4ABF-B2DB-B7A8E4E93377 Q55459882-8CC8BC70-0F1A-442C-833F-EB9BAB32101C Q58128443-CB0D1419-1DA6-4A30-B9D7-FCF9A216074C

P2860

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

http://www.wikidata.org/entity/Q34239292

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@ast

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@en

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@nl

type

label

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@ast

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@en

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@nl

prefLabel

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@ast

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@en

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@nl

P1433

Q34239292-014E0A78-43E4-4A0E-8644-99CF0DEB09F4

P1476

Q34239292-50768FB6-87E8-4664-9E77-42F574145D61

P2093

Q34239292-24A4CE76-D9A7-40ED-9E99-9D889E0C8668

Q34239292-381F21A4-5E47-47A7-A0C1-D6AEA3C3BE5C

Q34239292-485B9D6B-44D8-43AC-B855-DD00B9E3E6DB

Q34239292-55C2A9EA-2E35-4C33-913B-B51D774CEB57

Q34239292-A102DC96-A1BE-4B6C-9B12-8CCF956E3607

Q34239292-B266C42A-5B6D-4341-B59C-E2F7C8AFC87D

Q34239292-B9907E5C-CB73-46F6-8CF3-89D2901710C1

Q34239292-BBC37D75-54F7-4D5D-B687-1582F9F612A2

Q34239292-CB3C2A2D-B7CD-44EF-9423-FCEAA5A1B3EA

P2860

Q34239292-2040BAF6-B7E9-4396-8F73-0EF57A3E6B6D

Q34239292-3EA80079-C8F8-4BC0-A7F1-FF0E832A6A0D

Q34239292-5F338B09-3BFD-45C2-964F-8BE718BE9572

Q34239292-79D56342-BC34-4D3E-BE37-9CB0AFB6C687

Q34239292-7D678D4F-7E96-4ED7-ADA9-F520360735F4

Q34239292-8557243E-C5B0-407E-92AF-F564278176CD

Q34239292-8EAD1175-BB4F-4C71-B5B0-75974CDCCCB1

Q34239292-A1485E49-C80B-4051-AF4D-07DF2A69F573

Q34239292-A2A8ACC7-4301-462F-BFA8-F12493277358

Q34239292-AD00BD14-31EF-44D3-8F7A-A97A49D7C423

P304

Q34239292-179B5A06-B4AE-4492-900D-AEC070E44CF7

P31

Q34239292-4C158747-9CFD-4D43-9002-9A989B4B8EA3

P356

Q34239292-4AF8C1F1-FEE7-4655-9001-85C44EC50273

P407

Q34239292-BB156FC6-7F29-4C56-A540-D3392A920F20

P433

Q34239292-F0B91C0D-B7EB-408D-B879-D4ECC27536BE

P478

Q34239292-C692F3A3-A536-45EE-9394-5F738C0CAC65

P50

Q34239292-7A12A54D-1D8C-4A83-BC2B-182BC929B80A

Q34239292-7DCE36E0-DDAD-4527-AC53-AC21307C08E3

Q34239292-87536D0C-C3E6-4587-BFC4-01D28D4F3BCD

P577

Q34239292-65684594-CF5E-4614-88B2-0C1DFD5353AB

P5875

Q34239292-A33E5CE1-6ECA-4883-8842-9898396E8BE0

P698

Q34239292-92FBD563-3BCB-4DFF-B05F-D33FA0FE477E

P932

Q34239292-D77228B8-5472-4330-9983-40A00F44C1C1

P356

THORAXJNL-2014-205205

P1433

P1476

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

@en

P2093

A W Bill Musk

http://www.w3.org/2001/XMLSchema#string

Amanda Segal

http://www.w3.org/2001/XMLSchema#string

Bruce W S Robinson

http://www.w3.org/2001/XMLSchema#string

Ian M Dick

http://www.w3.org/2001/XMLSchema#string

Jenette Creaney

http://www.w3.org/2001/XMLSchema#string

Justine S Leon

http://www.w3.org/2001/XMLSchema#string

Steven J Skates

http://www.w3.org/2001/XMLSchema#string

Su Lyn Leong

http://www.w3.org/2001/XMLSchema#string

Yvonne Demelker

http://www.w3.org/2001/XMLSchema#string

P2860

EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.

Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion

The cytology of malignant mesothelioma.

Pleural effusions: the diagnostic separation of transudates and exudates.

Advances in malignant mesothelioma.

The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma

Problems in mesothelioma diagnosis.

P304

895-902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THORAXJNL-2014-205205

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Tarek M Meniawy

P577

2014-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264057035

http://www.w3.org/2001/XMLSchema#string

P698

25037982

http://www.w3.org/2001/XMLSchema#string

P932

4174124

http://www.w3.org/2001/XMLSchema#string